NCT04742101View on ClinicalTrials.gov

Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

March 10, 2021

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

S65487 and azacitidine

Treatment cycle of combination of S65487 and azacitidine during 4 weeks. Two administration schedules are set up. S65487 will be administered via intravenous (IV) infusion. Azacitidine will be administered via either subcutaneous (SC) or Intravenous (IV) infusion according to local practices.

Trial Locations (11)

28041

Hospital 12 de Octubre Servicio de Hematología, Madrid

31008

C. Universidad de Navarra Servicio de Hematologia, Pamplona

46026

H. Universitario La Fe Servicio de Hematologia, Valencia

94805

Institut Gustave Roussy, Villejuif

H-1083

Semmelweis Egyetem Belgyógyászati és Onkológiai Klinika Klinikai Farmakológiai Részleg, Budapest

44-102

Narodowy Instytut Onkologii im. M. Sklodowskiej-Curie Klinika Transplantacji Szpiku i Onkohematologii pokoj 4.041 ul. Wybrzeze Armii Krajowej 15, Gliwice

03080

Seoul National University Hospital - Department of Hematology-Oncology, Seoul

06351

Samsung Medical Center - Division of Hematology-Oncology, Seoul

EH4 2XU

Western General Hospital, Edinburgh

NW1 2PG

University College London - Hospitals NHS Foundation Trust, London

M20 4BX

The Christie NHS foundation Trust, Manchester

All Listed Sponsors
collaborator

ADIR, a Servier Group company

INDUSTRY

lead

Institut de Recherches Internationales Servier

OTHER